Last close As at 05/08/2026
GBP1.62
— 0.00 (0.00%)
Market capitalisation
GBP149m
Research: Real Estate
Phoenix Spree Deutschland (PSD) has completed the strategic sale of a 16-building portfolio of rental properties. Under its amended financing terms, PSD can now significantly accelerate condominium (condo) sales, exploiting the wide sales premium over investment property valuations. This is central to an orderly realisation strategy aimed at maximising shareholder value, which we believe is materially ahead of that implied by the share price. Disposal proceeds will first be used to repay existing debt ahead of the 2026 maturity, although refinancing options to accelerate shareholder distributions are possible.
Phoenix Spree Deutschland |
Enhanced realisation strategy to unlock value |
Asset sale and |
Real estate |
17 December 2024 |
Share price performance
Business description
Analyst
Phoenix Spree Deutschland is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||
Phoenix Spree Deutschland (PSD) has completed the strategic sale of a 16-building portfolio of rental properties. Under its amended financing terms, PSD can now significantly accelerate condominium (condo) sales, exploiting the wide sales premium over investment property valuations. This is central to an orderly realisation strategy aimed at maximising shareholder value, which we believe is materially ahead of that implied by the share price. Disposal proceeds will first be used to repay existing debt ahead of the 2026 maturity, although refinancing options to accelerate shareholder distributions are possible.
Year end |
PBT* |
EPS |
NAV**/ |
DPS |
P/E |
P/NAV |
Yield |
12/21 |
45.3 |
39 |
5.65 |
7.5 |
4.8 |
0.33 |
4.0 |
12/22 |
(17.5) |
(17) |
5.10 |
2.4 |
N/A |
0.36 |
1.3 |
12/23 |
(111.8) |
(107) |
3.96 |
0.0 |
N/A |
0.47 |
0.0 |
Note: *As reported on an IFRS basis including realised and unrealised gains. **Measured as EPRA net tangible assets per share.
Following the 16-building sale, the remaining portfolio comprises 75 buildings. Of these, 61 (c 1,700 units) are primarily (80% of the units) legally split as condos. The other 14 buildings (c 500 units) are not split and will be operated as private rental properties. Under the new debt arrangements, the number of buildings that PSD is able to market as condos at any point in time has increased from six to 40, representing c 950 units. An initial phase of 16 buildings, including those already available for sale, will be marketed by end-2024, a further 24 by mid-2025, and further buildings will be added, subject to future financing arrangements. PSD is targeting an increase in condo sales to €50m pa by end-2025, increasing thereafter, and has already strengthened its sales capability by engaging two of the leading sales platforms.
The portfolio was sold to funds managed by Partners Group for €76m, most of which will be used to repay borrowings, with the balance available for capex and general corporate purposes. The net loan to value ratio (LTV) is expected to reduce to 42.7% (H124: 46.5%). The cost of debt will increase slightly (to 2.9% from 2.6%). While this strategic portfolio sale will reduce EPRA NTA by c 8%, from €3.68 per share at H124 to a pro-forma €3.39, it is the key to unlocking material value within the wider portfolio. Condo sales in FY24 have been at an average €4,122 per sqm, a 19% premium to the external portfolio valuation, which is mostly on a ‘rental valuation basis’, with just 5% on the higher ‘condo’ basis. PSD expects half of the portfolio buildings to be valued on a condo basis at end-FY24 and says that current market evidence supports achievable condo sales values of c €5,000 per sqm for vacant units and €3,500 for those occupied.
The board believes that the enhanced, managed realisation strategy will maximise shareholder returns and has brought forward (to 17 February) the continuation vote that was due by June 2025. Should this not pass, it will be required to consider alternatives, including voluntary liquidation. We will update our asset sale analysis conducted in June which highlighted the potential to at least maintain NAV, representing a very material uplift to the current share price.
|
|
Research: Healthcare
Recce received approval from the Indonesian Drug and Food Regulatory Authority, Badan POM (BPOM), to start its registrational Phase III study in Indonesia of RECCE® 327 topical gel (R327G) in diabetic foot infections (DFIs). This was the final hurdle that needed to be overcome before study enrolment can proceed, which is expected to start before the end of 2024. Top-line data from the 300-patient double-blinded Phase III study (with 200 patients in the R327 arm and 100 on placebo) are anticipated in late 2025. If positive, we expect Recce would be able to launch R327G in South-East Asia in H2 CY26, potentially marking the company’s transition to a commercial stage.